Method and composition for inhibiting human cholesterol esterase
AssigneeCV Therapeutics, Inc.
InventorsLouis G. Lange, III, Curtis A. Spilburg, Dayton T. Reardan
Life of this patent
Estimating the term…
Abstract
A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.
Claims16
A method for lowering serum cholesterol in humans comprising administering to a human by ingestion, a therapeutic amount of a very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 0.98 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.1 weight percent of inorganic sulfates wherein the high molecular weight sulfated polysaccharide is prepared by sulfating a very high molecular weight polysaccharide with a sulfur containing compound at a temperature less than about 20° C.
The method of claim 3 wherein the therapeutic amount of a high molecular weight sulfated polysaccharide is ingested simultaneously with food.
A method of lowering serum cholesterol in humans comprising ingesting a therapeutic amount of a non-absorbable high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of about 2, containing less than 0.98 weight percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.1 weight percent free sulfates, and having an average molecular weight greater than 2,000,000 Daltons wherein the high molecular weight sulfated polysaccharide is prepared by sulfating a very high molecular weight polysaccharide with a sulfur containing compound at a temperature less than about 20° C.
An inhibitor of human cholesterol absorption comprising a therapeutic amount of a very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 0.98 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.1 weight percent of inorganic sulfates wherein the high molecular weight sulfated polysaccharide is prepared by sulfating a very high molecular weight polysaccharide with a sulfur containing compound at a temperature less than about 20° C.
An inhibitor of human cholesterol esterase comprising from 10 mg to 5000 mg of a non-absorbable high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of about 2, containing less than 0.98 weight percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.1 weight percent free sulfates, and having an average molecular weight greater than 2,000,000 Daltons wherein the high molecular weight sulfated polysaccharide is prepared by sulfating a very high molecular weight polysaccharide with a sulfur containing compound at a temperature less than about 20° C.
Dependencies are inferred from the claim text.